Loading institutional data...
Loading institutional data...
Insufficient data to determine institutional momentum.
Data as of Q2 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
4/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$5.2M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 6 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -340%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 6 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $6.9M (at 2025-12-31) covers all $3.5M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2022-09-30 (10-Q). The cash figure is from 2025-12-31, so the two are not the same balance-sheet date — the schedule has not been refiled since.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-10-02
No standout strengths flagged.
Where each multiple sits in its own 5-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 5-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
Equity is the year-end figure. On average equity over the two year-ends, ROE is -327.8% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cost of Revenue | 43.8 | 47.1 | 45.7 | 48.1 | 55.0 | 88.8 |
| R&D | 3.9 | 7.9 | 14.2 | 16.3 | 16.1 | — |
| SG&A | 29.3 | 50.4 | 66.6 | 59.8 | 65.3 | 180.0 |
| Operating Income | -29.4 | -53.2 | -97.9 | -112.5 | -137.0 | -465.4 |
| Income Tax | 0.0 | 0.0 | 0.0 | — | — | — |
| Net Income | -56.8 | -80.5 | -98.5 | -111.8 | -134.5 | -543.7 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ISPC: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-10-02
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.9M 100.0% | $9.3M 100.0% | $9.9M 100.0% | $10.4M 100.0% | $11.1M 100.0% | $8.2M 100.0% |
| Cost of Revenue | $1.7M 88.8% | $5.1M 55.0% | $4.8M 48.1% | $4.8M 45.7% | $5.2M 47.1% | $3.6M 43.8% |
| Research & Development | — | $1.5M 16.1% | $1.6M 16.3% | $1.5M 14.2% | $879K 7.9% | $319K 3.9% |
| Selling, General & Admin | $3.5M 180.0% | $6.1M 65.3% | $5.9M 59.8% | $6.9M 66.6% | $5.6M 50.4% | $2.4M 29.3% |
| Total Operating Expenses | $10.9M 565.4% | $22.0M 237.0% | $21.1M 212.5% | $20.6M 197.9% | $17.1M 153.2% | $10.6M 129.4% |
| Operating Income | -$9.0M -465.4% | -$12.7M -137.0% | -$11.2M -112.5% | -$10.2M -97.9% | -$5.9M -53.2% | -$2.4M -29.4% |
| Interest Expense | $2K 0.1% | $174K 1.9% | $16K 0.2% | $239K 2.3% | $2.1M 18.9% | $2.1M 25.6% |
| Interest & Investment Income | $4K 0.2% | $44K 0.5% | $340K 3.4% | $169K 1.6% | $11K 0.1% | $437 0.0% |
| Other Income (Expense), net | -$1.5M -78.3% | $230K 2.5% | $70K 0.7% | -$60K -0.6% | -$3.0M -27.3% | -$2.2M -27.4% |
| Income Tax Expense | — | — | — | $0 0.0% | $0 0.0% | $0 0.0% |
| Net Income | -$10.5M -543.7% | -$12.5M -134.5% | -$11.1M -111.8% | -$10.2M -98.5% | -$9.0M -80.5% | -$4.7M -56.8% |
| Per Share | ||||||
| EPS (Basic) | $-2.28 | $-17.58 | $-24.55 | $-1.16 | $-2.09 | $-4.97 |
| EPS (Diluted) | $-2.28 | $-17.58 | $-24.55 | $-1.16 | $-2.09 | $-4.97 |
| Weighted Avg Shares (Basic) | 4.6M | 711K | 452K | 8.8M | 4.3M | 936K |
| Weighted Avg Shares (Diluted) | 4.6M | 711K | 452K | 8.8M | 4.3M | 936K |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1095 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-06-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.02T | 49.8× | — | 15.6× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,500 |
| JNJ | $617.0B | 23.2× | 19.6× | 6.5× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | 0.9× | 4,554 |
| ABBV | $464.4B | 111.4× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 3.9× | 4,062 |
| MRK | $356.0B | 19.8× | — | 5.5× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,683 |
| UNH | $333.8B | 28.1× | 19.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 2.7× | 3,258 |
| AZN | $243.3B | — | — | — | — | — | — | — | — | — | 1,402 |
| TMO | $242.1B | 36.9× | 31.3× | 5.4× | 3.9% | — | 15.0% | 12.6% | 7.0% | 3.7× | 2,528 |
| AMGN | $217.9B | 28.3× | 18.5× | 5.9× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.2× | 3,070 |
| GILD | $179.5B | 21.4× | 19.7× | 6.1× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,216 |
| ABT | $168.7B | 26.2× | 18.3× | 3.8× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 0.5× | 2,876 |
| PFE | $158.5B | 20.4× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,748 |
| DHR | $150.5B | 42.4× | 31.1× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,050 |
| ISRG | $140.4B | 49.8× | 38.7× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | -0.9× | 2,165 |
| VRTX | $127.9B | 33.0× | 28.0× | 10.7× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | -1.2× | 1,689 |
| BMY | $124.9B | 17.7× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,451 |
| CVS | $110.6B | 62.2× | 11.0× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | -0.9× | 2,009 |
| MDT | $110.5B | 23.2× | 14.5× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 6.2% | 2.8× | 2,050 |
| SYK | $105.6B | 32.8× | 18.2× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 1.8× | 2,183 |
| MCK | $105.2B | 23.5× | 16.6× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 0.4× | 1,943 |
| HCA | $92.4B | 15.1× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,288 |
| ELV | $83.8B | 15.3× | 14.4× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 2.9× | 1,560 |
| MRNA | $75.9B | — | — | 39.0× | -39.9% | 55.3% | -145% | -32.6% | -30.5% | — | 774 |
| REGN | $75.7B | 17.7× | 18.1× | 5.3× | 1.0% | — | 31.4% | 14.4% | 13.6% | -0.3× | 1,291 |
| CI | $71.5B | 12.2× | 8.0× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 8.1% | 2.0× | 1,638 |
| BSX | $61.7B | 22.0× | 12.1× | 3.1× | 19.9% | 69.0% | 14.4% | 11.9% | 11.8% | -0.3× | 1,430 |
| ISPC | $3M | — | — | 1.4× | -79.2% | 11.2% | -544% | -340% | -340% | — | 1 |
Peers = companies sharing ISPC's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.